Title: Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control (CEPACT)  
Study ID: [REMOVED]  
Date of Document: Approved 01/13/2016  
HumanStudiesSubcommittee (IRBII)
Department ofVeterans AffairsMedicalCenter
Research andDevelopment Service
3900Woodland Avenue•Philadelphia, PA19104•215-823-3003 •Fax:215-823-5171
IRBAPPROVAL -Amendment
Date:January13,2016
From: Terri M. Laufer,MD,ViceChairperson
Investigator: Judith A. Long, M.D.
Protocol: UsingPeerMentorsto SupportPACTTeamEffortstoImproveDiabetesControl (CEPACT)
ID:01373 Prom#: 0013Protocol*: N/A
Thefollowing itemswerereviewedandapprovedthroughExpedited Review:
•Amendment -Expandenrollment by115-69poorlycontrolled diabeticveteransand46mentors
(12/11/2015)
Expedited Approval[Expedited underFederalRegulation: 45CFR46.110(b)(2) /VARegulation: 38
CFR16.110(b)(2)] wasgrantedon01/13/2016. ThisExpedited reviewwillbereportedtothefully
convened HumanStudiesSubcommittee (IRBII) on 01/20/2016.
Thefollowing othercommittee reviewsare scheduled:
Research&DevelopmentCommittee [02/02/2016]
TheCorporalMichaelJ.CrescenzVAMCIRBisnotconnectedwith,hasnoauthorityover,andisnotresponsible forhuman
researchconducted atanyotherinstitution, exceptwhereaMemorandum ofUnderstanding specifiesotherwise. Separateconsent
forms,initialreviews,continuing reviews,amendments, andreportingofseriousadverseeventsarerequiredifthesamestudyis
conducted atmultipleinstitutions. .^—_^-^^———^———————
R&DService(151)
CMCVAMC Specific Protocol Summary
Content Requirements forIRBCommittee
ReviewCMCVAMC IRB
CMCVAMedical CenterInstitutional Review
Board
A.Protocol Title
1.FullProtocol Title: UsingPeerMentorsto Support PACTTeamEffortstoImproveDiabetes
Control(CEPACT)
2.DateofProtocol Summary andVersion#: Date12/15/2015; Version# 7
B.PrincipalInvestigator's FullNameandDegree:JudithA.Long,MD APPR0VE°t>vCMcw»^
C.Co-Investigator's FullNameandDegree: /l^/lb
D.Financial Sponsor (Providethe nameofthe agency, organization, companyorperson providing
fundsfortheresearch study.)HSR&D
E.Grant(Providethe nameofindividual whoholdsthegrantandthegrant number, ifapplicable.) N/A
F.Protocol Number(Providethe financialsponsor's protocolnumber, ifapplicable.) N/A
G.Institution(s) responsible fortheproject:
1.Forsingle-site studies-CMCVAMC istheonlyinstitution involved. YesXNoD
2.Formulti-center studies.
2.1.CMCVAMC istheCoordinating CenterinwhichthePIistheleadinvestigator. YesNo
n/aD
2.2.Providethe nameofthe Coordinating Center.YesNoN/A
2.3.Listthenameoftheothersitesinvolved.
2.4.Provide theFWAnumbers foreachoftheothersitesinvolved.
THEFOLLOWING INFORMATION MUSTBECMCVAMC-SPECIFIC. THATIS.SPECIFIC TOWHAT
WILLBEDONEWITHCMCVAMC-RECRUITED VETERANS.
H.Background and Significance: (Describe succinctly andclearlythe pastfindingswhichjustifythe
planforthisproject.Asummary oftherelevantliterature inthearea ofinterestand reportsof
previous studiesshouldbeincluded.)
Peer supportand particularly mentorshave been shownto help AfricanAmerican diabeticveterans
withpoordiabetes controlimprovetheirglucose control.Ongoingstudiesare testingwhether
mentorscan helpnon-veteransand populations includinga largersample size of women.Peer
mentorsmaybe particularly effective inaVAsettingwheremanypatientslack socialsupportanda
cultureof camaraderie isstrong. However, itis unknown ifimprovements persist once mentoring
stops,howtobestsustainsuch programs andwhetherpeersupportmodelswouldbeeffective in
veterans fromallethnicracialgroups.
Purpose of the Project:(Clearlyprovidethe purposeofthisresearch project.)
Inthisstudy,weproposearandomized controlled trialofpoorlycontrolled diabeticveterans inwhich
poorlycontrolledveteransofallrace/ethnicities firstenrollasmentees inaprogramfordiabeticveterans
and thenasmentors to test a modelof sustainability. Inaddition,givenagrowingliteraturethat beinga
mentorisgoodforyourhealthbesidesfromcreatingsustainability fortheprogram itmayhelpsustain
Page1 of 33
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
effects.Thisstudywillhave4arms:1.Usualcare(enrolledattwodifferenttimepoints);2.Peer
mentoringwherementorsareveteranswhowereonceinpoorcontrolbutarenowingoodcontrol;3.
Peermentoringwherethementoringcomesfromformermenteesfromarm2(mentoring FFM);and4.
Formermenteesfromarm2 not randomized tobecoming amentor.Ultimately weaimtocreate
programsthatcanservetosustainably supportVAPatientAlignedCareTeam(PACT)efforts.
Describethe ResearchQuestions orHypotheses (thatis,whatquestions areyoutryingtoaddress by
conducting theresearch.)
Our primary aims areasfollows.
1.Testtheeffectiveness ofa peermentormodelinamixedracepopulation ofpoorlycontrolled diabetic
veterans.
H1:Compared tousualcare,veterans inthepeermentorarmswillhaveimprovedhemoglobin
(HbA1c),bloodpressure, LDLlevels,DMqualityoflife,anddepression scoresregardless ofraceor
ethnicityattheendoftheintervention (testedat6months)andeffectswillpersist(testedat12and
18months).
2.Testtheeffectiveness ofusing former peermenteesaspeermentors.
H2:Compared tousualcare,veteranwhoreceivepeermentoring fromformermentees willhave
improvedhemoglobin (HbA1c),bloodpressure, LDLlevels,DMqualityoflife,anddepression scores
attheendofthe intervention (testedat6 months)andeffectswillpersist(testedat 12and18
months).
3.Assessthe effectsofbecominga mentoronthose whowere originally mentees.
H3:Compared topastmenteeswhoarenotrandomized tobecomingamentor,pastmentees
randomized tobecomingamentorwillhavebetterglucosecontrol,bloodpressure, LDLlevels,DM
quality of life,anddepression scores.
4.Conductarigorousqualitative evaluation examining in-depththementor-mentee relationship, the
transitiontobecomingamentor,qualitiesofasuccessful mentor,andfactorsrelevanttobroader
program implementation.
Secondary Aims:
5.Inthoserandomized tobeingamentee,explorementorcharacteristics associated withimproved
HbA1c.Predictors tobeevaluated includepastmentoring doseofthecurrentmentor,thementor's
pastchangeinHbA1c,thementor'sstartingHbA1c,currentmentoringdoseprovidedbythementor,
mentee's evaluation ofthementor, and mentor's depression scoreatbaseline.
I.PrimaryOutcomeVariable(s): (Definetheprimaryoutcomevariable(s) usedtosupportthestudy
objectives (e.g.iftheobjectiveistoshowthattreatmentAissuperiortotreatmentBinthetreatment
ofsubjectswithessentialhypertension, theprimaryoutcomevariableisbloodpressure
measurement.)
Theprimaryoutcomevariablewillbechangeinglucosecontrolasmeasured bytheHbA1cassessed
atbaseline, 6months,12monthsand18months.
J.Secondary OutcomeVariable(s): (Definethesecondary outcomevariables.Suchmeasured
variables shouldalsoincludethetiming of measurement.)
Secondary outcomevariables willincludebloodpressure,serumLDL,diabetesqualityoflife
measured bytheselfreportedDiabetesDistressScale,anddepression assessedwiththePRIME-
MDPatientHealthQuestionnaire (PHQ-9). Allsecondary outcomes willalsobemeasured at
baseline, 6monthsand12months.
Page2 of 33
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
K.StudyDesignandMethods:
1.Isthis aclinicaltrial? XYES QNO
1.1.Ifyes, whattype? Check allthatapply.
PhaseIPhaseIIXPhaseIIIPhaseIV
1.2.Ifyes,thisstudymustbe registered onClinicaltrials.gov.
Design
2.1.Whatresearch me
XSurveys/Questionnaires
Behavioral Observations
DFocusGroups
XControl Group
XSpecimen Collection
DOther(Describe)hodswillbeusedintheproject? Checkallthatapply
XInterviews
DChartReviews
XRandomization
Placebo
DDeceptionAudioTaping
DVideoTaping
D Double-Blind
D Withhold/Delay Treatment
XTelephone Survey
2.2.Describe howrandomization orothertreatment assignment willbemade.
Afterinformed consentisobtained and thebaseline interviewis complete, participants willbe
randomized. Randomization willbe astagedprocess(seefigure 1). For both steps,
randomization willbeconducted bythe study statistician usingarandomnumbergeneratorand
viapermuted blockrandomization withvariableblocksizetoforcebalanceamongtreatment
groupassignmentsafterevery blockofparticipants isenrolled.
Atstage1,interested participants willberandomized tousualcareorpeermentoring. Atstage2,
interested participants willberandomized tousualcareorpeer mentoring fromaformermentee
(FFM).Inaddition,formermenteeswithberandomized toeitherbecomingamentororusualcare
(i.e.menteeassigned or nomenteeassigned).
Todate wehavebeen randomizing patientsina1:1manner.Afterreceiving IRBapprovalforthis
modification wewillchangeto 2:1randomization (2toanintervention armforevery1enrolled
intousualcare).Seebelow for exactnumbers.
Figure1Randomization
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage3 of 33
R&DService(151)
Stage2
RandomizationPeer
Mentoring FFM
UsualCare
2.3.Forretrospective researchstudies,providethe"look-back" period,(e.g.,December 1,
1999throughDecember 31, 2008.)
StudyDuration
3.1.Providethe estimated lengthoftimetoenrollallsubjectsand completethestudy.
Wewanttoenrollatotalof492poorlycontrolled diabeticveteransand206mentorswithcurrently
goodglucosecontrol.Instage1therewillbe206poorlycontrolleddiabetics inthepeer
mentoring armand206mentors.Mentorswhowithdrawfromthestudywillbereplacedby
additional mentorstoensure that all206poorlycontrolled diabetics inthepeer-mentoring arm
havementors. Instagetwotherewillbe144mentors(formermentees) ofwhich72willbe
randomized tobeingamentorand72willberandomized tousualcare.Inaddition,therewillbe
128poorcontrolleddiabetics56ofwhomwillbeinusualcareand72ofwhomwillberandomized
toreceivingpeermentoring fromFFM.Weprojectbeingabletoenroll7-8newpoorlycontrolled
diabeticsperweekwithtworesearchassistants. Evenconsidering thestaggered starttimes,we
anticipate itwilltake14-16monthstocompleteenrollment andanother18-24monthstocomplete
follow-upforatotalof38-40months.Afterthatweanticipate itwilltakeanadditional 1-2months
tocompletetheanalysis.Seesamplesizesectionforfurtherdescription ofrequiredsample.
3.2.Explaintheexpecteddurationofsubjectparticipation includinganyfollow-up.
Theactivetimeforeachparticipant inthestudywillberoughly18-24monthsdepending
onwhicharmtheyarerandomized to.12-18monthsofface-tofacevisitswithan
additional 6 monthsafterthe last in-person visitwhereeach participant's electronic
medicalrecord(EMR)willbeunderelectronic review.Figure2depictstheflowof
participants throughthestudy.
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage4 of 33
R&DService(151)
ARMl
Stage1
RandomizationFigure2:Flowof Participants Through Study
Stage1
Mentors
J. 6Months: ,
 Assessment 12Months:
Assessment
UsualCare
Baseline^06Months: H
MM Assessment MM12Months:
Assessment
ARM4^H NoMentee^J^K Assigned__12Months:
Assessment
Mentees
Baselineft_J Mentee^|^HAssigned 12Months:
AssessmentARM2
ARM3^HMentoring FFMWM
HK Baseline H||6Months:
Assessment
Stage2 1
Randomization iIkUsualCarem
VI Baseline §r
6Months:
AssessmentARMl18Months:
EMR
18Months:
EMR
18Months:
Assessment
18Months:
Assessment
12Months:
Assessment
12Months:
Assessment24Months:
EMR
24Months:
EMR
18Months:
EMR
18Months:
EMR
3.3. Specify the projected dateofcompletion ofthe proposed study.
Enrollment startedSeptember 27,2012and we anticipate completion ofthe studyby
December 31,2015
4.DrugInformation (Ifnotapplicablestate, "NotApplicable.") N/A
4.1.Specifyifthedrug or biological agentis:
4.1.1. FDAapproved
4.1.2. Usedforoff-label purposes
4.1.3. Not yet FDA approved.
4.2.IncludetheFDAInvestigational NewDrug(IND)numberfor allnon-FDAapprovedand
off-labeldrugs,biological agents or nutritional supplements. Ifnotapplicable state,"Not
Applicable."
4.3.Provide allrelevant information aboutthedrug
4.4.Explainanywash-out periods,rescuemedications permitted andanytypeof
medications not permitted whileenrolled inthe study.
4.5.Describe blindingandun-blinding procedures.
4.6.Includethedosage, routeofadministration, previoususe,andthesafetyand efficacy
information onanydrugusedforresearch purposes.
4.7.Describe rationale forthedosageinthisstudy.
4.8.Justifywhytherisksarereasonable inrelationtoanticipated benefitsand/orknowledge.
4.9.Describe wheredrugpreparation willbedone.
4.10.AlldrugsforCMCVAMC subjectsmustbedispensed throughtheVAinvestigational
pharmacy.
4.11.Describe where the study treatment willbeadministered.
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage5 of 33
R&DService (151)
4.12.Describeplanfor trackinganon-compliant treatmentstudysubject.
4.13.Summarize anypre-clinical data.
4.14.Describethe process forthestorage, security,dispensing andreturnofan
investigational drug.
5.Investigational Device(Ifnotapplicable state,"NotApplicable.") N/A
5.1.TheInvestigational DeviceExemption (IDE)numbermustbesubmitted forallsignificant
riskdevicesandifan IDE existsfor anon-significant device.
5.2.Significant RiskorNon-significant Risk-Ifadeviceisnotapproved bytheFDA,specify
whether or notthe sponsorhas determinedthisdeviceto be a "significant risk"or"non
significant risk"asdefinedbytheFDA.
5.3.Provide allrelevant information aboutthedevice.
5.4.Describe blindingandun-blinding procedures.
5.5.Specifyifdeviceis:
5.5.1. FDAapproved
5.5.2. Usedforoff-label purposes
5.5.3. NotyetFDAapproved.
5.6.Explainiftheinvestigational devicewillbedelivered and/orstored bythe Principal
Investigator orPharmacy Services.
5.7. Describe the processforthestorage,security,dispensing and returnofan
investigational device.
5.8. For research involvinganinvestigational device,describe the SOP or planfordevice
control.
5.9.Address howthedevicewillbestoredinsucha waythatonlyresearch staffassociated
withtheprotocol willhaveaccesstothedevice.
5.10.Describe measures thatwillbe put intoplace to ensurethat the device willonlybe used
inparticipants ofthisresearch protocol.
L.Doesthis projectinvolve international research? DYESXNO
1.Forfurtherinstructionsreferto VHADirective 2005-050. Requirements forConducting VA-
Approved International Research Involving HumanSubjects, HumanBiological Specimens, or
Human Data
2.VHAHandbook 1200.05 definition ofinternational research -VAinternational research isany
VA-approved researchconducted atinternational sites(notwithintheUnitedStates(U.S.),its
territories, orCommonwealths); anyVA-approved researchusingeither humanbiological
specimens (identified, de-identified, orcoded)orhumandata(identified, de-identified, or
coded)originating frominternational sites;orany VA-approved researchsendingsuch
specimens ordataoutoftheU.S.(seepar.56).NOTE:Forthepurposes ofthisHandbook,
research conducted atU.S.militarybases,ships,orembassies isnot considered international
research.
M.StudyProcedure
1.StudyProcedures
1.1.Outlineallstudyprocedures- (Ifnecessary, includeatableorflowchart,showingthe
scheduleofthe procedures andinteractions. Distinguish betweeninterventions thatare
experimental andcarriedoutforresearchpurposes vs.thosethatareconsidered
standard ofcare.Routineprocedures thatareperformed solelyforresearchpurposes
shouldalsobeidentified.)
Overview: Wewillperforma randomized controlled trialwithfourarms. The aimistocreate a
program that can augment PACTefforts.
Page6 of 33
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
Patients andSettings: Wewillenrollveterans withdiabetes mellitus(DM)who receivetheircare
fromtheCMCVAMedical Center(CMCVAMC). Veterans between theagesof30and75years
ofage- patients most likelyto reap the benefits ofgainingcontrol- willbeeligiblefor
participation. Therewillbe 4 arms: 1.Usualcare (enrolledat twodifferenttime points);2.Peer
mentoring where mentorsareveterans who were onceinpoorcontrol butare nowingood
control; 3. Peermentoring wherethementoring comesfromformermentees from arm 2
(mentoring FFM);and 4. Former mentees fromarm 2 not randomized to becoming a mentor. To
ensurethatwearetargeting thosemostlikelyto benefit from improvingcontrol we enroll diabetics
withpersistently poorDMcontrol.Persistently poorDMcontrolwillbedefinedashaving an
HbA1c>8%on2different occasions inthecourseof24months, withatleast1measure within3
monthsofenrollment. Mentors for arm 2 willhavepreviously beeninpoorcontrolandarenow in
good control,defined ashavingan HbA1cof>8% inthe past 3 years and an HbA1c<7.5%
within3monthsofenrollment. They willalso,whenfeasible, be thesamerace, sex, and age(±
10years)astheirmentee. Whenpossible, ifthementeeis on insulinwe willseekout amentor
on insulin. Thesecriteria for selecting bothmentees andmentors haveled tosuccessful
mentoring partnerships inour priorwork. Patients willbeidentified bytheCenterforEvaluationof
PACT (CEPACT) through VISN4 DataWarehouse (VDW).WithIRBapproval, CEPACT will
extractadministrative, clinical,andlaboratory datafromtheVDW on an ongoing basis.TheVDW
isupdatedregularly and thusanexcellent sourceofup-to-date patientinformation. Identified
patients willbesenta letterdescribing thestudyand then called. The PI hasusedthis method to
identifyveterans withDMon many occasions and routinelyis ableenrollbetween 60-70% of
thosecontacted. Potential mentors forarm2 willbeidentified andapproached in asimilar
manner. Veterans whoagreetoparticipate willbe invitedinto theCMCVAMCtocomplete a
consentprocedure, baseline survey, and havetheir blood drawn to determine theirHbA1cat
enrollment. Allenrollees andmentors willreceive,regardless ofthearm,$50.00foreachvisit
requiring a blood draw and surveycompletion (baseline, 6 months, 12 months, and depending on
arm,potentially 18months).
Attheendof 6months,thoserandomized toreceiving amentorinstage1willbere-randomized
toeitherbecoming amentor(arm 2) or not becoming amentor(arm 4). Thosewho do not
become amentorwillcontinue tobefollowed. Thoserandomized tobeingamentorwillbecome
mentorsfor arm 3 participants. For arm 3, matching willbe tailored to the bestofourabilitysince
the poolof mentors willbelimitedtothosewhowere previously mentees. We have builtinover-
enrollment intostage1to allowfor someloss to follow-upand selective removal of participants
who mightbe inappropriate mentors. Potential menteesforstage2willbeidentified and
contacted inthesamemannerasthoseidentified for stage1.Thoseinterested inparticipating
willberandomized tousualcareormentoring from FFM. As with stage1,participants willreceive
$50toreimburse themfortheirtimefor allrequired inpersonvisits.
Procedures: Asmentioned therewillbe4arms.Randomization intoeacharmisdescribed above.
Arm1UsualCare:Theywillcomplete allplanned surveys, interviewsand blooddraws (baseline,
6 months, 12months). Inaddition, allparticipants' medical health record willbeunderelectronic
review for an additional 6monthsaftertheirlastvisit.Theywillbe notified of theirstartingHbA1c
andtheAmerican Diabetes Association (ADA)andVArecommended goalsforHbA1c.No
additional interventions willbe provided. Allparticipants willbe called at onemonth and three
monthstocheckinandassessforhypoglycemic events(basedon ourpastprevious work we
anticipate thattheseeventswillbe rare and not differbyarm).
Arm2 PeerMentoring: Inadditionto being notifiedoftheirstarting HbA1candADAandVA
recommendations forHbA1c,arm 2willbe toldthatwithinthenext 1-3weekswewillfindthem a
peermentorwhowillstartcallingthem.Theywillbetoldthattheyare expectedto talkwiththe
mentoratleastonceaweekfor 6monthsbut they can talk asmuchasthey want. We willalso
Page7 of 33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
explainthatwewillnotbesettingupaface-to-face introduction butthatitisfineforthetwoof
themto meet inperson ifthey desire. Finally,participants willbe remindedthat insixmonths
timethey maybecome a mentor.Wewilltrainthemto be mentorsand providethemwitha
menteewhois inpoordiabetes control.
Afterbeingrandomizedtothe peer mentorarmwe willidentifypotentialmentorsand contact
peopleuntilaneligiblementor isfound. Mentors willparticipate inan hourlongone-on-one
traininginformed bymotivational interviewing techniques. Alltrainingmaterialshave been
developed and include instruction on learningthe mentee's story,understandingthe mentee's
motivations, helpingthe menteeidentifythe differences between their behaviors and goals, and
helpingthe menteeidentifya realisticplanforgoal achievement. Open endedquestions are
encouraged and modeled. Mentors are also taught howto follow-up andassessprogress.
Samplequestions willbe provided. However, mentors are also encouraged to drawontheirown
experiences. Once a month,peer mentors willbe contacted to providetrainingreinforcement and
askedabouttheirinteractions withtheirmentee. Peermentors willbegiventhephonenumberof
theirmenteeand informedthat they willreceive $20 per monthfor speaking atleastonce a week.
Whether theyspokewillbedetermined byself-report.
Attheendof6months,atthefirstfollow-upvisit mentees willberandomly assigned tobecomea
mentorortonotbecome amentor.Thoseselected tobecome amentorwillbetrainedhowtobe
mentors andtoldthatwewillcontacttheminthenext1-3weekswith amentee. Theywillthenbe
askedto performallofthe activitiesthat theirmentor performedforthem. Liketheirmentors, they
willalsoreceive$20permonthfor talking at leastonceaweek.
Arm3 PeerMentoring FFM:Aswiththe other arms the participants willbenotifiedoftheirstarting
HbA1candADAandVArecommendations forHbA1c. Tothebestofourability, Arm 3 willbe
matched witha mentor race, sex, age(±10years), and insulinuse. The mentor willcome from
Arm 2andinitiatephonecontact.
Arm4 Former Mentees notRandomized toBecoming aMentor:Arm 2participants not
randomized to becoming a mentor willbefollowedinthesamemannerasarm 2 participants
randomized tobecoming amentor.
Page8 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
Data Collection: Allparticipants (mentors andmentees) willcomplete abaselinesurvey, a short
callat 1and3 months, a 6 month survey, a 12 month survey, a blood draw at baseline, 6 months,
and12monthsandwillhavetheirmedical healthrecordunderelectronic reviewforanadditional
6monthsafterthelastin-person visit.Thoserandomized to arm 2 andfurtherrandomized to arm
4 willreceiveadditional shortcallsat7monthsand9monthsandhaveoneadditional inperson
visit with blood drawat18months. Asampleofmentors andmentees fromstage1andstage2
willbeaskedtocomplete qualitative interviews baseline, 6, 12, 18 months.Table1 identifies data
tobecollected ateachtimepointandthesourceofthedata.
Table1:Measurement Schedule
Baseline 1
M3
M6
M12
M18
M24
M
Dependent Variables
HbAic(blood) X X X X
BloodPressure (inpersonmeasurement) X X X X
DirectLDL(blood) X X X X
DMqualityof Life(self-report) -Distress X X X X
Depression Symptoms (self-report) -Mood X X X X
Intervening Variables ofInterest
SocialSupport X X X X
Self-Efficacy (self-report) X X X X
Perceived Benefits andBarriers (self-report) X X X X
Self-management Behaviors (self-report) X X X X
PastMentoring DoseReceived byCurrent Mentor(Pastrecords) X
Mentor's pastChange inHbAic(Past studyrecords) X
Mentee's assessment ofmentorquality(self-report) X X X
Potential Confounders
Demographics (self-report) X
Attachment Style(self-report) X
Perceived NeedforSupport (self-report) X X X X
BMI(inpersonmeasurement) X X X X
DMHealthHistory(self-report) X
General HealthHistory(self-report) X X X X
Potential Contamination (self-report) X X X
Hypoglycemic Symptoms (self-report) X X X X X X
Qualitative Perceptions ofProgram (self-report) X X X X
Medical RecordReview (Electronic medical record)** X X
* Current Mentoring DoseProvidedbyMentorwillbe assessedmonthly.ForEaseof Presentation wedidnot includeall
collection times.
** Exacttiming of EMRreviewdependsonarm- onlyreviewedonceeitherat 18or 24months.
Forself-reported datawewillusevalidated surveyquestions developed bythe PIor other
researchers inthefield.Theresearch coordinator willbetrainedtomeasure BPandpulserateat
eachvisitusing an automatic digitalbloodpressure monitoronthe non-dominantarm afterthe
subjecthasbeenseatedfor5 minutes.An averageoftwomeasurements willbe used for
analyses. Wewillevaluate bothchangeinsystolicand diastolicBPas wellas the percent of
patientsineacharm with ADAtargetBP (BP< 130/80mmHG). Heightand weight willbe
measured usingstandard procedures witha beam balance and a strain-gauge digitalscale,
respectively, andusedtocalculate bodymassindex(BMI).
Wewillconductthe qualitative interviews withthe aim of understanding how,intermsofthe
outcome HbA1c,successful mentor-mentee pairs differedfrom thosewhowere not successful.
Interviewguideswillbeinformedbyadultlearningtheory.Wewillusesemi-structured interviews.
Open-ended questions willbefollowedbyprobes to promptdetailand ensurethat a broadrange
ofpossible responses areelicited.Usingconstant comparisontechniques, we willmodifyscripts
inrealtimeasnewandunexpected themesemerge.
1.2.Explain if andhowthefollow-up of subjects willoccur.
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage9 of 33
R&DService(151)
Follow-up willoccurat 1 and 3 monthspostenrollment witha brief phonecall, and at 6 months
and12monthspostenrollment at the CMCVAMedical Center.Additional shortcalls at 7 and 9
monthsandan additional in person18month visit willalsooccurforthoseinarm 2 and 4. After
follow-up in personvisitsarecomplete, allenrolled participants' medicalhealthrecordwillbe
underelectronic reviewforanadditional 6months.
1.3.Describe where,howandwhowillbeconducting studyprocedures.
Consent, studysurveysandinterviews, blood pressure measurements, and weight at baseline, 6
months, 12monthsandwhenappropriate 18monthswilloccurattheCMCVAMedical Center
andbeperformed by aprojectmanager orresearch assistant.
Oneandthreemonth hypoglycemic assessments willbeassessed over the phonebya project
manager orresearch assistant.
Evaluations oftheserumHbA1candLDLwillbeperformed bytheCMC VAMedical Centerlab.
Electronic reviewofmedical healthrecords willoccurattheCMCVAMedical CenterontheVA
servernetwork.
1.4.Ifasurveystudy,specifytheestimated amountoftimethatsubjects willneedto
complete thequestionnaires/tools.
Thebelowtableestimates theamountof timeeachstepwillrequirefordatacollection. The
amountof timespentonmentoring callsis notdetermined bythestudy.
Table2: DataCollection Step,TimetoComplete andModeofCollection
Procedure Estimated Timeto
CompleteNumber ofTimesto
Perform
Consent 30minutes 1 (inperson)
Baseline Survey 45minutes 1 (inperson)
Labtests 10minutes 3-4(inperson)
Hypoglycemic Symptoms 5minutes 2(phonecall)
Follow-up Survey 30minutes 2-3(inperson)
Qualitative Interviews 20minutes 2-3(inperson)
Healthrecordreview 15minutes 1(electronically)
MentorTraining 60minutes 1 (inperson)
Reinforcement Calls 10-15minutes 5(phonecall)
Estimated TotalActiveTimeforParticipants
Arm1 175minutes (=3.0hours)
Arm2 385minutes (=6.5hours)
Arm3 215minutes (=3.5hours)
Arm4 385minutes («6.5hours)
Mentors forArm2 325minutes (=5.5hours)
Based on experience, consent willtake about 30 minutes and the baseline survey willtake
approximately 45minutes. Follow-up visitswilltake about30minutesforsurvey completion and
20 minutesforthe completionofqualitative interviews. The lab usually expedites testsfor
research and we expect patients willneed tospendapproximately 10minutesgettingtheir blood
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage10of33
R&DService (151)
drawn.Thetotaltimecommitment forconsent anddatacollection isestimated tobebetween 3
and 7 hoursdependingonthe armthe personis in.However, giventhetimecommitment wewill
reimburse participants$50foreach inpersonvisitto covertimeand transportationcosts and an
additional$40 forqualitativeinterviewsifthey agreeto complete the qualitative interview portion
ofthestudy.
1.5.Ifa blooddraw,specifythe amount of bloodto bedrawnin millilitersandinteaspoonfuls
ortablespoonfuls andspecify how often and wherethe blood willbe drawn.
BlooddrawswilloccurattheCMCVAMClab. We anticipate a maximum of 5ccsor 1teaspoon of
bloodwillbe requiredforeach in-person visitat baseline, 6 months, 12months and when appropriate
18months..
2.DataCollection (Includeall questionnaires and survey tools withthe submission.)
2.1. Provide
2.1.1. themodeofdatacollection, e.g. telephone, in-person, questionnaire,
interviews,
Datawillbe collected mostlybyin-person survey, interviewand lab tests.Inaddition, mentors
willreceiveshortreinforcement callseachmonthatwhichtimewewillcollectdataabouthow
manytimesthe mentortalkedtothe mentee inthe month.Hypoglycemic symptoms willbe
assessed byphone at 1and 3 months (additionally at 7 and 9 months forarms 2 and 4).
Electronic medical records willbereviewed 6monthsafterthelastinpersonvisit.SeeTable1
and2fordetails.
2.1.2. thepreciseplan for how datais to becollected oracquired
Surveys willbe read to participantsand answers willeither be directlyinputintoa computer
database orwrittenonto paperforms and then transferred to adatabaseat a later time. The
databasewillresideonVAservers behindtheVAfirewallandwillneverberemoved fromthe
server.Paperrecordswillbe stored at CHERP behindan electronically lockedentrance, a key-
lockeddoorandin akey-locked cabinet.
Qualitative interviews willalso bereadtoparticipants andanswers willbe voice recorded.
Interview datawillbestoredontheVAserverandwillbebehindVAfirewalls Thisdatawillbe
temporarily sharedwithAlphaTranscription, andUniversity ofPennsylvania's MixedMethods
Research Lab,transcribing andcodingrespectively. Bothcompaniesare approvedvendors with
appropriate VAapproved datasecurityinplace.
Dataaboutthenumberofcalls per month madebythe mentor willbe collected over the phone,
andagainresponses willeitherbeentered directlyintoa database or firstontopaperandthen
intothedatabase.
Dataabout hypoglycemic symptoms willbecollectedoverthe phoneand responses willeitherbe
entereddirectlyintoadatabase orfirstontopaperand then ontothe database.
Labresultswillbeobtained fromthelab or via CPRSandenteredintothesecureresearch
database.
Chartswillbeabstracted foradditional HbA1c,LDL,and blood pressure readings 6 months after
thelastface-to-face visit.
2.1.3. exactlocation wheredatawillbecollected,
Page11of 33
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
CMCVAMCandtheCMCVAMC Annex (forin person,phoneandchartderiveddata).
2.1.4. exactlocationwheredataentrywilltakeplace.
Alldata entry willoccur either at the CMCVAMCortheCMCVAMCAnnex.Paperfilesforthe
studywillbehousedat theCMCVAMCannexinlocked filingcabinets. Data willbe stored on VA
servers behindtheVAfirewall..
2.1.5. the"title"ofindividual(s) collecting thedataandanalyzing thedata,e.g.
principal investigator, research coordinator.
AProject manager and/orresearch coordinators willbe collecting dataand entering itintothe
database. ThePrincipal investigator andamaster's levelprogrammer willbeanalyzing thedata.
Identifiable datawillnotberemoved fromCMCVAMCservers. Access toidentifiable datawillbe
limitedto thosewhorequireaccessincluding theprojectmanager andresearch coordinators,
principal investigator, andtheprogrammer.
2.2.Provide atimeline foreachaspectofthestudy.
Baseline: Obtain consent, complete baseline survey,randomize, obtainblood.
For arm 2 (and 4) also: Identifymentor, obtain consentfrom mentor, complete mentorbaseline
survey,trainmentor,obtain blood from mentor, havementorstartcallingmentee.
6months:Complete followup survey,interviews, andblood for mentors andmentees.
For arm 2 also: Train arm 2 participants to bementors andmatchthemtomentees (participants
inarm3).
12 months: Complete followup survey, interviews, and obtain blood from arms1, 2, 3, and 4.
18months:Complete followup survey, interviews, and obtain blood from arms2, and 4.
18months-24 months: Monitor electronic healthrecordforarm1, 2, 3,and4.
Ongoing:Callallmentors every monthto reinforcetrainingand determine mentor-mentee call
frequency. Call allmentees at 1 and 3 monthstoassesshypoglycemic symptoms.
2.3.Chart/Records/Data Review(retrospective and/orprospective)
2.3.1. Providetheplannedorapproximate numberofcharts/records/data to be
accessed
2.3.1.1. CMCVAMC
Given our previous experience we anticipate havingto screenbetween 1,600-2,000 chartsto
identify492poorlycontrolled diabeticveterans and 206mentorswho willbeeligibleandwillingto
participate.
Similarlyweexpecttoscreen 1000additional chartstoidentify206mentorswhoare eligibleand
willingto participate, as wellasmentors to replace thosewhowithdraw.
2.3.1.2. Othersite
2.3.2.Doesthis protocolemployan Honest Broker?DYESXNO
2.3.2.1. Ifyes, provide nameof individual.
2.3.2.2. Ifno, explain who willaccessthecharts/records.
Page12 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
2.3.2.3. Describe fromwhatdatabase charts/records/data willbeaccessed.
3.FutureUseofDataandRe-Contact, ifapplicable. N/A
3.1.Ifanyoftheparticipant's dataaregoingto beretained afterthestudyforfuture
research, thefollowing information mustbeprovided totheparticipant:
3.1.1.Where willthedatabestored?
3.1.2.Whowillhaveaccess tothedata?
3.2. If thesubjectisgoingtobere-contacted inthefutureaboutparticipating infuture
research, thismustbespecified. Describe thecircumstances underwhichthe
participant wouldbere-contacted whether withintheVAoroutsidetheVA.
3.2.1. Ifsubjects willreceiveaggregate studyresultsattheendofthestudy,the
informed consent document mustcontain thisinformation.
4.Specimen Collection
4.1.Givethesourceof allspecimens andwhether theywerecollected forresearch,
treatment ordiagnosis.
Bloodwillbedrawntoassess HbA1canddirectLDLonthree-four different occasions for
research purposes. Treatment decisions willnotbebasedonresultsbytheresearch team.
4.2.Statewherespecimens willbestored,secured andwhendiscarded.
Specimens willbedrawnbytheCMC VA MedicalCenterlabanddisposed ofappropriately. We
willnotbestoringbloodforfutureuse.
4.3.Explainhowdestruction ofsamples willbesubstantiated.
TheCMC VA MedicalCenterlab willhandlebloodsamples inthesamewaytheyhandlesamples
forroutineclinicalcareandsubjecttotheoversight ofroutineclinicalcare.
N.Genetic Testing, ifapplicable N/A ,
1.Explainifthestudyis looking for anassociation between ageneticmarkerandaspecific
disease orcondition, butatthispointit isnotclearifthegeneticmarkerhaspredictive value.
1.1.Theuncertainty regarding thepredictive valueofthegeneticmarkerissuchthatstudies
inthiscategory willnot involve participant counseling.
1.2.Describe ifthestudyisbasedonthepremise thata linkbetween ageneticmarkerand
aspecificdisease orcondition issuchthatthemarkeris clinically usefulinpredicting
thedevelopment ofthatspecificdisease orcondition.
1.3.Willthesubjectbe notified of theresultsandtheprovision for geneticcounseling?
 Yes DNoDN/A
1.3.1. Ifyes,explainfurther.
1.4.Ifbiological specimens areusedinthisprotocol, pleaserespond tothefollowing
questions bychecking the appropriate box:
a.Doestheprojectinvolvegenetictesting?
b.Willspecimens bekeptforfuture,unspecified use?
c.Willsamples bemadeanonymous tomaintain confidentiality?
(Instructions: Note:Ifthereisalink,itisnotanonymous. Coding
isnotanonymous.
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage13of33YES


NON/A



R&DService (151)
1.5.
1.6.d.Willspecimens bedestroyed aftertheproject-specific useis
completed?
e. Willspecimens besoldinthefuture?
f.Willsubjects be paid for theirspecimens now or in thefuture?
Willsubjects beinformed oftheresultsofthespecimen
testing?
h. Arethereanyimplications for family members basedon
specimen testingresults? (Ifyes,theymaybeparticipants.)
Willsubjects beinformed ofresultsobtained fromtheirDNA?
Willspecimens be de-identified? DYES DNO N/A
1.5.1. Ifyes,pleasedescribe theprocedures to beused.
1.5.2. Includeatwhatpoint intheprocessthespecimens willbede-identified.
Describe whatmeasures willbetakentominimize thefollowing risksfrombreaches of
confidentiality andprivacyresulting fromparticipating inTHISaspectoftheresearch
project:
1.6.1. physical
1.6.2. psychological
1.6.3. financial
1.6.4. social
1.6.5. legalharm
O.Banking ofCollected Specimens
1. Will collected specimens bebanked? DYESXNOQN/A
1.1.IFBANKING SPECIMENS. ITMUSTBEATANAPPROVED VAREPOSITORY. (For
additional information, refertoVHAHandbook 1200.12, UseofDataandData
Repositories inVHAResearch - March9, 2009.)
1.2.Ifyes,specifythelocationwherespecimens willbebanked.
1.2.1.Ifthelocation is a non-VA site,hasthemandatory approval fromtheChief
OfficerofResearch andDevelopment (CRADO) beenobtained through
submission of atissuebankingapplication (VAForm 10-0436 - Off-site
Application foranOff-siteTissueBankingWaiver)? QYESQNOQN/A
1.2.2.Ifapplicable, attachacopyoftheVAForm 10-0436
1.3.Explain how destruction ofbankedsamples willbesubstantiated.
P.SubjectRecruitment (characteristics ofthestudypopulation)
1.Providetheplanned ortargeted enrollment at:
1.1.CMCVAMC -492poorlycontrolled diabeticveterans and206mentors, aswellas
mentors toreplacethosewhowithdraw.
1.2.Othersites-
1.3.Notapplicable; chartrevieworuse ofpreviously collecteddata -
2.Screening and/orEligibility Requirements
2.1.Describe andprovidejustification for:
2.1.1. Inclusion criteria
Allparticipants and mentors willbe type 2 diabetics. To be eligiblethey must have developed
diabetesaftertheageof30. To ensurethat we are targeting thosemostlikelyto benefit from
improving controlweenrolldiabetics withpersistently poorDMcontrol.Persistently poorDMcontrol
willbe defined ashaving an HbAlc>8% on 2 different occasions inthecourseof24 months, withat
least1measure within 3 monthsofenrollment. Mentors forarm2 willhavepreviously beeninpoor
controland are nowingood control,defined as havingan HbAlcof>8% inthe past 3 years and an
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage14 of 33
 


 
 
R&DService(151)
HbAlc<7.5%within3 months ofenrollment. Also,toensurethat we are targeting thosemostlikely
to benefitfrom improving control, participants willneedto bebetweentheagesof30-75.
2.1.2. Exclusion criteria
Wewillhaveminimalexclusioncriteria. Patients willbe excluded ifthey do not speakEnglishorare
unabletounderstand theconsents asexhibited byfailingthe miniquiz.Patients willalso be
excluded ifthey have a severespeechimpediment ofany kind sincetheyneedto be able to
converse withamentorormenteeover thetelephone. Patientsover theageof75willalso be
excluded sinceitisuncleariftheywillderive the samebenefit from getting their HbAlcincontrol.
2.2. Listall screening and/oreligibility requirements.
Wewillelectronically createa listofCMCVAMC patientswithatleasttwodiagnosis codesfor
diabetes (ICD-10code 250) and least twolaboratory testsinforanHbAlc.Wewillexclude people if
theircurrentageiss30and> 75yearsofage.Wewillthenreviewthelistanddetermine who
qualifiesasa potential menteeand a potential mentor. Letters willbesentto potential participants
lettingthem knowthat they may be eligiblefora study witha briefdescription ofthe study and give
them anumberifthey would liketo learn more orto requestnofurther contact. We willalsonotify
potential participants that ifwe do not hearfromthem we willgivethem a callinthe following weeks.
Potential mentors willbeidentified andcontacted in asimilarmanner.
2.3. Explainany specialtestorevaluations potential subjectsmay have to undergo before
theyareactuallydetermined to be eligiblefor thestudy.
When patients are contacted overthe phone we willgivethem an additionaldescription ofthe study
and forthoseinterested wewillaskthem at what agetheydeveloped diabetes. Thosewho indicate
theydeveloped diabetes before the ageof30willbeexcluded from participating. The samewillbe
true forwhen we contact potentialmentors. We willalso ask them about howcomfortablethey are
withspeaking English. Thosewho indicate discomfort withspeaking Englishor are unintelligible
overthephonewillalsobeexcluded from participating.
2.4. NotApplicable; subjects not recruited; chartreview.
3.Ifapplicable, indicate whatpopulations willbetargeted forrecruitment asparticipants.
Check a1thatapply.
Males X
Females X
Inpatients 
Outpatients X
VAEmployees 
Non-English Speaking** 
Veteran Familymembers*** 
Non-Veterans*** 
Other(Specify) 
NotApplicable, chartreview 
3.1.**Fornon-English speaking subjects - Ifaninvestigator proposes touseaparticipant
population thatdoesnotspeakorreadEnglish, acopyofthetranslated document, as
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage15 of 33
R&DService(151)
7.wellastheEnglish version, needsto be forwarded to the IRBfor approval. Translator
certification isalsorequired.
3.2.***lfnon-veterans willbe recruited forthis study, explain whysufficient veterans are not
available to participate inthe project FVHAHandbook 1200.5. paragraph 16a].Veteran's
spouses/partners, caregivers, etc.areconsidered non-veterans forthepurposes ofthis
study.
3.3.***Hasapproval torecruitnon-veterans beenreceived fromtheACOS/R&D and
Medical Center Director?
3.3.1. X NotApplicable
3.3.2. Pending(Non-veteran formsshouldbeused.IRBofficewillobtain
approval fromACOS/R&D andMedical CenterDirector.)
Doesthisprojecttargetaspecificrace orethnicgroupasparticipants? DYESXNO
Ifyes,checkallthatapply.
Race
American IndianorAlaskan Native 
Asian 
BlackorAfrican American 
NativeHawaiian orotherPacific
Islander
Black, not of Hispanic origin 
White,notofHispanic origin 
Other Ethnicity
Hispanic orLatino 
NotHispanic orLatino c
Other c
4.1.Providejustification why this/these group(s) was/were chosen
Whatistheagerangeofparticipants? Checkallthatappy
Children (Under18)Requires Waiver fromCRADO (VHA
Directive 2001-028. Research Involving Children)
YoungAdults(18-21)
Adults(22-65)
Seniors (Over65)
Over89
NotApplicable, chartreview



Aretherespecificreasonswhycertainpopulations (i.e.,age,genderorethnicgroups)
areexcluded asparticipants? IEIYESXNOQN/A
6.1. Ifyes, specify reasons. We excluded people inthe agegroupsyoungerthan 30years
andolderthan75yearsofage.Patients undertheageof 30wereexcluded toensure
weareidentifyinga population withtype 2 diabetes, andpatientsover theageof75will
alsobeexcluded sinceitisuncleariftheywillderive the samebenefit from getting their
HbAlc incontrol.
Doestheprojectrequireenrollment ofthefollowing classesofparticipants?
YES NO
a.Employees  X
b.Individuals withimpaired decision makingcapability  X
c.Pregnant women  X
d.Economically and/oreducationally disadvantaged persons  X
e.Prisoners  X
f.Illiterate, limited,ornoEnglishlanguage proficiency a X
g.Terminally illpatients a X
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage16 of33
R&DService (151)
Whilethe study doesnotrequirethe enrollmentof thesegroups weanticipatethatwe willenroll
economicallyand/or educationally disadvantaged people as wellas people who may have limited
healthliteracy. Allstudy materials including consent forms willbe read to participants. Onlythose
whofailthemini-quiz and thus seemnottocomprehend theconsentprocess willbe excluded.
7.1.Ifapplicable, what isthe justificationfor includingany ofthe aboveclassesof
participants intheproject?
7.2. If theprojectrequiresenrolling any of theaboveclassesofparticipants describe any
project-specific measures or special considerations, steps,orsafeguards toensurethat
theseindividuals areadequately protected.
8.Describe theexactplanhowsubjects willbeidentified andrecruited forthestudy.
8.1.Discussmethods, e.g.,referralsfrom physician offices, clinics, programs, or through
advertisements andbrochures.
Wewillelectronically createa listofCMCVAMC patientswithatleasttwodiagnosis codesfor
diabetes (ICD-9code250 and ICD10codesstarting with E11)and atleasttwo laboratory testsinfor
anHbAlc.Wewillexclude peopleiftheircurrentageis^30and> 75yearsofage.Wewillthen
reviewthelistanddetermine whoqualifies asapotential menteeandapotential mentorbasedon
pastHbAlcvalues.Thiswillbe anongoing process.
Letterswillbesentto potential participants lettingthem know thatthey may be eligiblefor a study
with a brief description ofthestudyandgivethemanumberoftheprojectmanager who they can
callifthey would liketo learn more or to requestnofurther contact. We willalsonotifypotential
participants that ifwe do not hearfromthem we willgivethem a callinthe following weeks.
Potential mentors willbeidentified andcontacted in asimilarmanner.
Whenpatientsarecontacted over the phone we willgivethem additional description ofthe study
andforthoseinterested wewillaskthematwhatagetheydeveloped diabetes. Thosewho indicate
they developed diabetes before the ageof30willbe excluded fromparticipating. Thesamewillbe
true forwhen we contactpotential mentors. Wewillalsoaskthemabouthowcomfortable they are
withspeaking English. Thosewho indicate discomfortwith speaking Englishor are unintelligible
overthephonewillalsobeexcluded from participating.
Thoseinterested in participating in thestudywillbe invitedinto theCMCVAMCfor afaceto face
meetingwiththe study team. Atthat time ifstillinterested participantsand mentors willcomplete the
consentprocessinperson including completinga mini-quiz about the process. Thosewhofailthe
mini-quiz willbe excluded fromthe studyatthat time;however, theywillbe reimbursedthe $50for
cominginforan inperson visit.We anticipatealmosteveryonewhocomes infora face toface visit
willbeentered intothestudy.
9.
9.1.Ifusing aclinic,be specificabout who willidentifythe potentialsubject and howthat
information willbetransmitted totheresearch staff.
9.2. If snowball methodwillbeused,discusstheprocessandhowthefirst individuals willbe
recruited.
9.3.Describe howinformation willbedisseminated tosubjects, e.g.handouts, brochures,
flyersand advertisements (includeallrecruitment materials withthissubmission).
10.Informed Consent
10.1.Informed Consent willnot be sought. 
10.2. Written informed consentfromparticipants (VAForm10-1086 isattached). X
Page17of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
10.3.Writteninformed consentfromparticipants' legallyauthorized representative (LAR)as
required by VApolicyand/or applicable statelaws(VAForm10-1086isattached). 
10.4.RequestWaiver ofDocumentation ofInformed Consent
10.5.Listthetitleofthekeypersonnel involved in thefollowing activities:
10.5.1. PersonObtaining Consent
10.5.1.1. Provide thetitle(s)ofindividual(s) Program Specialist
10.5.1.2. Typeoftrainingreceived toperformthisprocessCPRStraining,
CITItraining, HIPPAtraining, andscanner training.
10.5.2. Pre-Recruitment Screening (theuseofmedical recordsandotherdata
basestodetermine populations andindividuals eligibleforthestudy),Data
BaseProgrammer andProjectManager orProgram Specialist
10.5.3. Recruitment Process (theprocess inwhichindividuals arecontacted and
firstintroduced tothestudyandtothepossibility of participating assubjects),
ProjectManager orProgram Specialist
10.5.4. Informed Consent Process (theprocessbywhich recruited subjects arefully
informed aboutparticipating inthestudyandthenformally give theirvoluntary
consent forparticipating), ProjectManager orProgram Specialist
10.5.5. Screening ofRecruited Subjects (thoseactivities intheprotocol inwhich a
finaldetermination of eligibilityof prospective subjects ismadeduringthe
earlyphasesofthestudy,usinglaboratory data,inclusion andexclusion
criteria,andotherperson-specific information), ProjectManager orProgram
Specialist
10.5.6. Includethebreakdown ofeachindividual's responsibilities:
10.5.6.1. Principal Investigator, JudithA.Long, M.D.willberesponsible
fortheoversight ofthisentirestudy
10.5.6.2. Co-Principal Investigator, N/A
10.5.6.3. TheProjectManager Jennifer Gutierrez orResearch Coordinator,
Tanisha DicksorotherIRBapproved research staffwillbe
responsible fortheIRBadministration, screening, therecruitment
andconsent, datacollection including measuring BMI,blood
pressure, andinterviews (overthephoneandin-person). They
willalsoberesponsible fortrainingthementors andmentee-
mentor coordination.
10.5.6.4. Additional research staffby title,TheProjectManager Jennifer
Gutierrez orResearch Coordinator, Tanisha Dickswillbe
responsible forIRBadministration.
10.6.Willinformed consent beobtained frompotential subjects prior todetermining eligibility?
Dyes xnoQn/a
10.6.1. Ifno,providejustification andaHIPAAWaiverof Individual Authorization for
Disclosure ofProtected Health Information.
Tomaketherecruitment process efficient wewillneedtoscreenforpatients with
diabetes, inthecorrectagerange,withthelabresultsasdescribed above.Pleasesee
theattached HIPAAWaiver ofIndividual Authorization forDisclosure ofProtected Health
Information forapproval ofthisactivity.
10.7.Definewhenasubjectisenrolled intothestudy,e.g.afterthesubjectsignstheinformed
consent orafterrandomized totreatment.
Aftertheinformed consent iscomplete thepatientwillbeenrolled inthestudy.
10.8. Describe:
Page18 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
10.8.1. Theprocesswheninformed consent willbeobtained andprotecting patients'
privacy.
Informed consent willbeobtained attheCMC VA MedicalCenterin asemi-private room
withcubicles. Thisroomusuallyhasonlyonepersonworking in itat a timeandthus
affordsaudioprivacy. Allstudymaterials including informed consent formswillberead
totheparticipant.
10.8.2. Anywaitingperiodbetween informing theprospective participant and
obtaining consent. No
10.8.3. Stepstakento minimize thepossibility of coercion orundueinfluence.
Theconsent process willexplainhowparticipation isvoluntary andwillnotaffectthe
careorservices thepatientiseligiblefromthePhiladelphia VAMedicalSystem.
Participants willbetoldtheycanwithdraw fromthestudyatanytime.Participants will
onlyreceiveareimbursement todefraythecostsoftravelandcovertheparticipant's
time.
10.9.Providethelanguage
10.9.1. usedbythoseobtaining consent Pleaseseeattached script.
9.9.2 understood bytheprospective participant orthelegallyauthorized
representative Pleaseseeattached script.
10.10. Provide location whereinformed consent willbeobtained. TheCMCVAMedical
Center
11.WaiverorAlteration ofInformed Consent Requirements/Waiver ofRequirement to
Obtain Documentation ofInformed Consent
11.1.Are you requesting awaiveroralteration ofinformed consent? (Checkallthatapply)
11.1.1. NoX
11.1.2. Yes; provide justification. 
11.1.3. Yes;forrecruitment purposes only.
11.1.3.1. An IRBmayapprove aconsent procedure whichdoesnot
include, orwhichalters,someoralloftheelements ofinformed
consent setforthinthissection, orwaivetherequirements to
obtaininformed consent provided theIRBfindsanddocuments
that:
•1.Theresearch involves no more thanminimalriskto the
subjects;
•2. The waiver or alteration willnotadversely affectthe
rightsandwelfareofthesubjects;
•3. Theresearch could not practicably be carried outwithout
thewaiveroralteration; and
t4.Whenever appropriate, the subjects willbe provided
withadditional pertinent information afterparticipation
•  5. Theresearch ordemonstration project is to be
conducted by orsubjecttotheapproval ofstateor local
government officialsandisdesigned tostudy,evaluate, or
otherwise examine:
a.Publicbenefitorserviceprograms;
b.Procedures forobtaining benefits orservices under
thoseprograms;
c.Possible changes in oralternatives tothoseprograms or
procedures; or
Page19 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
d.Possible changes inmethods or levels of payment for
benefits orservices underthoseprograms.
11.2.Areyourequesting awaivertoobtaindocumentation ofinformed consent?
11.2.1. NoX
11.2.2. Yes; provide justification. 
11.2.2.1. AnIRBmaywaivetherequirement fortheinvestigator to
obtainasignedconsent form forsomeor allsubjects ifitfinds
either:
•1.That the onlyrecord linkingthesubjectand theresearch
wouldbetheconsent document andtheprincipal riskwould
bepotential harmresulting from abreachof confidentiality.
Eachsubjectwillbeaskedwhether thesubjectwants
documentation linkingthesubjectwiththeresearch, andthe
subject's wisheswillgovern;or
•D2.That the research presents no morethan minimalriskof
harmtosubjects andinvolves noprocedures forwhichwritten
consent isnormally required outsideoftheresearch context.
•NOTE: Incasesinwhichthedocumentation requirement is
waived, theIRBmayrequire theinvestigator to
provide subjects withawrittenstatement regarding the
research.
Q.Compensation (The amount ofcompensation may notconstitutean undue inducement to participate in
theresearch.)
1.Summarize any financial compensation thatwillbe offered to subjects.
Allparticipants willreceive$50foreachinpersonvisit.Mentors willalsoreceiveanadditional
$20permonthiftheycalltheirmentee4timesperweek.Mentors andmentees willreceivean
additional $40foreachqualitative interview completed.
2.Providetheschedule forcompensation. Baseline, 6months, 12months, andforarm2and4
18months.
2.1.Perstudyvisitorsession. $50
2.2. Total amountforentire participation. Arm1$150,Arm2up to $460, Arm 3up to$270,
Arm4upto$320.
3. Explain how compensation willbeprovided viacash,voucher, giftcard,etc.Participants willbe
givenvouchers whichtheycanthenredeemforcashfromtheCMCVAcashier.
4. Iffinancial compensation willbeprorated, explaintheprocess. N/A
5. NotApplicable- 
R.Withdrawal/Early Withdrawal
1.Describe howandwhenasubjectmaywithdrawal fromthestudy.Subjects maywithdraw at
anytime.Anyrequestmayeitherbeexpressed verbally or inwriting.
2. Provide procedures forthe orderly termination ofparticipation bythe participant and ifany
consequences wouldresultfromearlywithdrawal fromthestudy.
Therewillbe noconsequence ofearly withdrawal. Aftersubmitting a requestto withdraw or
written or verbally the studyparticipation willbeterminated. Ifamentorwithdraws before 4
months, hisorhermentee willbere-matched toanother mentor.
3. Explainifsurvival datais required. Ifso,clarifyhowdatawillbe obtained. N/A
4. Not Applicable; subjects notrecruited; chartreview.
Page20 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
S.Risk/Benefit Assessment
1.Potential StudyRisks
1.1.Describe andassessallofthefollowing risksthatmay beassociated withtheresearch:
1.1.1. Physical Minimal
1.1.2. Psychological Minimal
1.1.3. SocialMinimal
1.1.4. Economic Minimal
1.1.5. Monetary Minimal
1.1.6. LegalMinimal
1.1.7. Lossofconfidentiality Minimal
1.1.8. Assess thelikelihood andseriousness ofsuchrisks.Minimal
1.1.9. Other
1.2.Specifywhatstepswillbetakentominimize theserisks.
Patients willneedtocomplete a mini-quiz aftercompleting theinformed consenttoassurethe
researchers theyunderstand theconsentprocedure. Thosewho failthemini-quiz willbe given
$50 fortheinpersonvisitbut not enrolled in thestudy.Allparticipants willbe notifiedthat
participation isvoluntary andtheycanterminate participation at any time. They willalsobe
notifiedthattheircarewillnot beaffected bytheir participation.
Thegreatest risk topatients willbelossofconfidentiality. Mentors andmentees willbe
informed thattheirconversations areconfidential andshouldnotbeshared. Mentees willneed
toprovideaworking phonenumberwhichwillbeprovided tothementor. Mentees willbe
informed ofthisprocess up-front.
Tracking datawith identifiable information willbe kept ina different databasethantheanalytic
database.Alldatabases willbepassword protected andresideon VAservers. Neitherdata
basewillberemoved fromtheVAserverandwillbebehindVAfirewalls. Paperfileswillbe
kept in locked filingcabinets andwillnotleavetheCMCVAMCor Annex. Paperswillbe kept in
locked files whennot being actively used.Allparticipants willbe given a studyIDnumberand
thiswillbetheonly link between theanalyticfilesandthetrackingdatabase.
1.3.Ifmethods ofresearch createpotential risks, describe othermethods, ifany, that were
considered andwhytheywillnotbeused.N/A
1.4.Ifchartreview,breachofconfidentiality isalwaysaconcern. Specifywhatstepswillbe
takentominimize theserisks.
Chartswillbereviewed todetermine ifapotential subjectmay be eligible for thestudy.Only
IRBapproved studypersonnel willaccesschartsfrom VA computers during work hours.
Abstraction willbelimitedtodetermine eligibility only.
Chartwillalsobereviewed 6monthsafterthelastin-person visithastakenplace(andforthose
losttofollow-up shouldhavetakenplace).Minimaldatawillbeabstract fromthechart-
additional HbAlc, LDLs,andBPmeasurements fromthetimeofentryintothestudytotheday
ofthechartabstraction. Onlythosewith IRB approval willabstract thisdataanditwillonly be
doneontheVApremises. Datawrittenonpaperabstraction toolswillbeentered intothe
analyticdatabase housebehindtheVAfirewall. Paperdocuments willbekeptonsiteandin
lockedfilingcabinets intheCMC VAMC Annex.
2.Potential StudyBenefits
Page21 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
2.1.Assessthepotential benefitsto begainedbythe individual subject,aswellasbenefits
thatmayaccruetosocietyingeneralasa result of theplannedwork.
Inour pilotstudy, poorlycontrolled diabetics who received mentoring on averageimprovedtheir
HbAlcby 1%. This is a large andclinically significant improvement. If improvements persist
thentheparticipant mayreducehis orherrisk offuturecomplications fromdiabetes. This
studyin partwillhelp usunderstand betterifriskspersist.Thisstudyhasthe potential alsoto
addto ourknowledge abouthow tobettertosupportdiabetics ingeneralwithbehavioral
change.
2.2. If thesubjectdoesnotreceiveanydirectbenefit,thenitmustbestatedhereandinthe
consent form.
While we hopethatsubjectwillreceivebenefititislikelythatsomeparticipants willnot benefit
especially thosewhoarerandomized tousualcare.
3.Alternate Procedures
3.1Describe thealternatives available tothesubjectoutsidetheresearch context. N/A
3.2Ifnone,statethatthealternative is not to takepartinthisresearch studyatall.The
onlyalternative istonottakepartintheresearch study.
T. Data andSafetyMonitoring Board(DSMB) or DataMonitoring Committee (DMC)(AllPhaseIII
studiesarerequired tohaveaDSMB. However, theIRBhastherighttoreguire aDSMBwithany
study.)
1.Willanindependent DSMBorDMCoverseethe project? IEIYES DNODN/A
2.1.Ifyes,pleaseprovidecontactinformation for theDSMBor DMCor Coordinating Center
Representative andattachacopyofthecharter.
Name:JoshuaMetlay MD PhoneNumber: (610)519-9168
Title: DSMB Chair E-mail:jmetlay@exchange.upenn.edu
2.IfaDSMBor DMCwill notmonitorthisstudy,whowillmonitorthisstudy?Checkallthat
apply.
XPrincipal Investigator
 Sponsor
VACooperative Studies Program
 Safety monitoring committee
U.DataMonitoring (Monitoring plansdescribehowa monitor,independent ofthestudy team,regularly
inspects studyrecords toensurethestudyisadhering tothestudyprotocol andapplicable research
regulations andCMCVAMC reguirements. Monitoring plansdonotnecessarily reguiretheuseofan
independent DataandSafetyMonitoring Board(DSMB). Suchindependent boardsareusuallyreserved
forhigh-risk phaseIstudies, orlarge,multi-center phaseIIItrials.Federally fundedstudiesmayreguire
theuseofanindependent DSMB.)
1.Describe thedatamonitoring plan.(Allprotocols musthaveadatamonitoring plan
appropriate forthe potential risks andthe complexityofthe study.)
Hypoglycemic eventswillbemonitored at 1,3and 6 months. Allserious adverse events willbe
reviewed bythePIand reportedtothe IRBaswellas theDSMB.We do notexpect events to differ
by armbasedonourpriorresearch.
Page22 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
Datanot directly entered willbedoubleenteredtoensurefidelity.Paperconsents willbereviewed
routinely for completeness. Allfileswillberegularly maintained andavailable forinspection upon
request.
2.Describe howprotocol deviations, adverse events,seriousadverse events,breaches of
confidentiality, unanticipated adverse deviceeffect(UADE), andunanticipated or
unexpected problems willbereported totheCMCVAMC IRBandsponsor. (Refer to the
CMCVAMC IRBStandard Operating Procedure (SOP)Manual forreporting guidelines.)
Breaches ofconfidentiality willreported within24hoursofourawareness ofsaid
breach.
2.1.Describe themanagement ofinformation obtainthatmight be relevant toparticipant
protections suchas:
2.1.1. Unanticipated problems involving riskstosubjects orothers
This is a lowrisk study.However, if unanticipated problems arisethestudyteamwillreview them
andreportthemimmediately totheCMCVAMC IRB. If thereareseriousconcerns aboutrisksto
subjects orothersthestudywillbehaltedwhile an external groupreviewsthestudytodetermine the
risks.
2.1.2. Interim results
Wearenotplanning aninterimanalysis.
2.1.3. Protocol modifications
Ifwedesireto modify theprotocol wewillsubmitamodification totheIRBandnotactonthe
modification until ithasbeenapproved.
3.Ifapplicable, definetheplanforsubjects ifresearch showsresultssuchas:
3.1.Depression Wewillonlyuseadepression screening toolandnotassessing for
depression. Iftheparticipant iswillingandtheyscreenpositive fordepression we
willnotifytheparticipant's primary careprovider.
3.2.Suicide Willnotbeassessed
3.3.AbuseWillnotbeassessed
4.Statistical Analysis
4.1.Includestatistical powercalculations andtheassumptions madeinmakingthese
calculations.
Wewillrandomize 72mentees fromstage1 toeacharmofstage2. Toachieve80%powerto
detecta0.8unitchangeinHbAlc,withstandard deviation of1.6,asampleof 64patientsperarm
wouldberequired. But toprotectagainstpossible attrition, wewillinflatethatby10%andenroll
72participants intoeacharm.Literature andguidelines suggest thatanaverage decrease of 1
unitinHbAlcwouldprovide aclinically meaningful improvement inhealth.Wechosea0.8unit
changetobeconservative. Webaseourstandard deviation of1.6onourpilotstudyandother
studiesof lowcontrolDMpopulations.
Forstage2wewillalsorandomize poorlycontrolled diabetics intomentoring orusualcarearms.
Wewillneed72intheusualcarearm(tobementored bythe72stage1mentees whobecome
mentors). Sinceusualcareforstage2canbecombined withusualcareforstage1,thereis no
needfor a 1:1 randomization. Initially,a 1:1randomization wasused,butafterevaluation we
Page23 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
believewecannowswitchto a 2:1randomization to avoid recruiting moreusualcarepatients
thannecessary. Withthis changewewillenrollapproximately 56patientstousualcareinstage
2.
Inordertoassure72 ineacharmforstage2, wewillneedatotalof144mentees instage1.
Again, to protectagainstpossible attrition, we inflate thatby16%andenroll171mentees instage
1. Acorresponding numberofmentors (171)willberecruited forstage1.Therewillbe no
randomization ofmentors instage1.Sinceusualcareforstage1canbecombined withusual
careforstage2,thereis noneedfor a 1:1 randomization. Initially,a 1:1randomization wasused,
butafterevaluation webelievewecanswitchto a 2:1randomization toavoidrecruiting more
usualcarepatientsthannecessary. With this changewewillenrollapproximately 139patientsto
usualcareinstage1.
Thecombined numberof poorly controlled diabetic patientsreceiving usualcarewillbe
approximately 195.Thenumberof poorly controlled diabeticpatientsreceiving peermentoring
willbe232(171instage1and72 instage2).Thenumberofmentors instage1willbe171,and
thenumberofmentors instage2willbe72 (from amongthosewhoreceived mentoring instage
1).Thetotalnumberofpatients inthestudywillbe594.
Arecentanalysis of clinical datafromtheCMCVAMCanditssurrounding CBOCsindicatethatin
thelastyeartherewere1,248patientswho would havequalified to be mentees and1,810who
wouldhavequalified tobementors.
4.2.Defineplansfordataandstatistical analysis, including key elements ofthestatistical
plan,stopping rulesandendpoints.
ForStage1:Wewilltesttheseprimaryhypotheses usinganunadjusted intent-to-treat analyses,
i.e., with adjustment for onlybaseline HbAlc.Theprimarytestswillassessthesignificance ofthe
coefficients associated withthetreatment assignment in alongitudinal linearmodelofthe
repeated HbAlcasa function of treatment, wheretheactivegroup(peermentoring) iscompared
tothecontrolgroupvia anindicator variable. Standard t-testswilldetermine whether a significant
difference inHblAcimprovement occurred between thetreatment armcompared tothecontrol
arm. Toaccountforthefactthatwearedoing multiple tests,wewillusetheBonferroni method
andconsider atreatment tobesignificantly different thanthecontrolifthep-valueislessthan
0.05/2=0.025.
Stage2Analysis:
H2.Compared tousualcare,veterans whoreceivepeermentoring fromformermentees willhave
improved glucose controlasmeasured byHbAioBP,LDLlevels,DMqualityoflife,anddepression
scores:Wewillexamine theeffectiveness oftheintervention at6months andfurtherexamine
sustainability at12and 18months.18 month assessments willonly be of HbA1c,BP, and LDLlevelsas
derivedfromtheEMR.We willtesttheseprimaryhypotheses using an intent-to-treat (ITT)analyses, i.e.,
including allpatientswhocompleted abaselineassessment, asrandomized. We willuselinear and
random effects longitudinal models to performtheITTcomparisons ateachofthefollow-up visits.Our
primaryoutcomes willbeHbA1c,BP,LDLlevels,DMquality of life,anddepression scores.Our models
willinclude a randomeffect for patient. Themodelswillinclude the following fixed effects: a main effect
forfollow-up visit(withbaselinevisitas the reference), intervention group, and theirinteractions. Testsof
theinteraction termswillbeusedtodetermine theITTdifference between groupswithrespecttochange
frombaseline. Toexamine whether veterans whoreceived peermentoring fromformermentees have
improvedglucose control,BP,LDLlevels,DMqualityof life,anddepression scorescompared to
veterans inthe usual caregroupat 6months,compared tobaseline, wewillimplement theserandom
effectsmodelswithmenteeHbA1c,BP,LDL,DMquality of life score,ordepression scoreasthe
dependent variable.The ITTtestforeffectiveness willbebasedonHbA1candwillbe two-sided, with
Page24 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
alpha=0.05 andwillbebasedonthemagnitude andstatistical significance ofthetime*intervention
interaction termat 6months. Toexamine sustainability ofimprovement inglucosecontrol, BP, LDL
levels,DMquality of life, anddepression scoreswewillusethesametest,butwillexamine the
intervention group*12 monthtimeinteraction term.Toexamine sustainability ofimprovement inglucose
control, BP, andLDLlevelsat18monthswewillagainusethesametest,butwillexamine the
intervention group*18 monthinteraction term.
Wewillcheckmodelfit byinspecting residual plots,andwillassessimprovement infitwith different
correlation structures fortherandomeffects.Whilewedo notanticipate confounding inourITTestimates
because ofthestratified andblocked randomization ofpatients, confounding duetoimbalance inpatient
characteristics may still occurbychance.Testsforevidence ofconfounding willbeperformed by
comparing baseline characteristics, between controlandintervention group.Confounders willbe
identified asvariables thataresignificant atthe0.20levelandwewillincludetheseasadjustment
variables (fixedeffects)inouranalyses. Thesemultivariable modelswillreducetheimpactofpotential
biasduetoconfounding, aswellasimprove thestatistical powerbyreducing theamountofunexplained
variation intheoutcome variable.
Extensive effortswillbemadetocollectcomplete information oneachparticipant enrolled inthestudy.
While we do not expecttobeconfronted withnonignorable missingdata,wewillnevertheless assessthe
sensitivity oftreatment effectestimates tomissingoutcome datain anumberofways.Wewillcompare
thenumberof visitscompleted byparticipants ineacharmasanadditional secondary outcome, using
thechi-square test.Wewillalsocompare observed characteristics ofsubjects withcomplete follow-up to
thosewithmissingdataandwillattempttoascertain thereasonsformissingdatainsubjects with
incomplete follow-up.
H3:Compared topastmentees whoarenotrandomized tobecoming amentor, pastmentees
randomized tobecoming amentor willhavebetterglucose control. BP,LDLlevels.DMgualitvoflife,and
depression scores:Toexamine whether pastmentees whobecome mentors havebetterglucose control,
BP, LDL levels,DMqualityof life,anddepression scoresthanpastmentees whodo notbecome
mentors, thedependent variable inthisanalysis willbepastmentee HbA1c,BP,LDLlevel,DMquality of
lifescore,anddepression scoreandtheintervention groupwillbetherandomization groupforformer
mentees. Aswedescribed above,testsoftheinteraction termsforeachfollow-up time(i.e. 6,12months,
and18months) withintervention groupwillbeusedtodetermine theITTdifference between groupswith
respecttochangefrombaseline HbA1c,BP,LDLlevel, ateachfollow-uptime andDMquality of life
score,anddepression scoreat 6and12months.
Testing ofSecondary Quantitative Hypotheses:
H4.Inthoserandomized tobeingamentee. explore mentorcharacteristics associated withimproved
outcomes. Predictors tobeevaluated includepastmentoring doseofthecurrentmentor,thementor's
pastchangeinHbA1c,thementor's startingHbA1c,currentmentoring doseprovided by thementor, the
mentee's evaluation ofthementor,andthementor's depression scoreatbaseline. Basedonthe
literature andour pilotstudies,wehaveoptedtousepastmentees asmentors regardless of a. time
passedsincetheywereamentee, b.theamountimprovement inHbA1cwhentheywereamentee, or c.
their starting HbA1cinthis study. We willevaluate ifany ofthesementorvariables areassociated with
menteechangeinHbAic,BP,LDLlevel,DMquality of life score,anddepression scoreat 6 and 12
monthsandHbAic,BP,andLDLlevelat18months.
Assessment ofHypoglycemia: Inordertoassesstherelativefrequency ofminorhypoglycemic symptoms
wewillsummarize thenumberofparticipants ineachstudyarmreporting 0, 1-3, or >3 minor
hypoglycemic symptoms per month. Inorder to compare averagerates per person per month, usingall
available data,wewillfitageneralized linear mixed model withrandom subjectintercepts andtestfor
differences between treatment groups.Basedon ourprevious studyweexpectvery few major
hypoglycemic events, we willcompare differences byarm usinga Fisher's exact test. Ifrequested bythe
Page25 of 33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
DataSafetyMonitoring Board(DSMB- seeSectionE.5inHumanSubjects), preliminary analysesof
minorand major hypoglycemic eventswillbecompleted beforethe completion ofthestudy.
Qualitative Analyses:
ProcessEvaluation:Tofacilitate later deployment ofresults and to improvethe designoffuture
interventions, wewillengageinaqualitative process evaluationthroughoutthe studyto learn whysome
studyparticipants succeed inchanging behaviorand othersdo not,andwhatelementsoftheapproach
wereacceptable toparticipants.115 Inparticular, weareinterested inlearningaboutthementor-mentee
relationship. Allinterviews willbe audio-taped, transcribed, and content-analyzed. We willuse the
framework ofadultlearningtheoryto analyze the results.We willlookforevidence ofthe following from
successful mentormenteepairs:1.thementeeexpressed a perceived a need to change,2.theprocess
was relevant to the mentee's needs,3. theprocessmotivated the menteetochange,4. thementeefelt
thementorlistenedtothementeeandsupported thementee's identified goals,5.Thementorwas
motivated to be amentor,6.thementortailored their approach totheneedsofthementee, and6.the
mentorfostered andenhanced thementee's senseofself-efficacy regarding diabetic healthbehaviors.
However, whilewe use the lens ofadult learningtheory toguide the analysis we willkeep an open mind
tothepotentialthat thisframework does notadequately characterize allaspectsofsuccessful pairsand
willlookforcommon themesthat mightlieoutside ofthis framework. Following thisprocessofcareful
readingandreflecting upontheinterviewtranscriptsand discussingthemamongourselves willprovide
anopportunity tounderstand the mechanismsby whichpeermentoring operates and identifythemes that
emergefromthedata.
Afterextensive discussion ofthetranscripts andidentification of important themes,wewillgenerate a
WorkingCodingScheme(WCS)basedonthe theoretical modeland refineitthrough content
evaluation ofthefirstfew interviews. Oncewehavedeveloped aninitialWCS, Dr. Long andtheproject
manager willindependently recode the content ofthe already coded interviews, and through an
iterativeprocesswithDr.Shea,discrepancies willbe resolved untilafinalcodingschemeisdeveloped.
Thissimilar processofdouble coding withresolutionof disagreements willthen be appliedto codingall
thetranscripts.
ThefinalWCSwillbeusedasan analytic toolfor identifying patternsinthe data, answering conceptual
researchquestions, and generating new hypotheses grounded inthe data. Foranalysis oftranscripts,
wewilluseNVivosoftware forqualitative dataanalysis. We willuse the software to develop counts of
codesstratified by changeinHbA1caswellasbythementor's pastexperience withreceiving
mentoring (optimal/suboptimal) and the mentor's past successwithimproving theirHbA1c.We have
used thisanalyticapproach previously and found itameaningful waybywhichtoidentifythemesand
understand theemphasis placed onthe theme bythe populations as a whole. Theseanalyses willbe
used to refinethe conceptual modeland expand our understandingofhowpeer mentoring functions. In
addition,comparisons willbe made todetermine ifthere isthematicconsistency between mentorsand
mentees.
Bycollecting qualitative datasequentially inconjunction withthequantitative studywe willbeableto
interpretandcontextualize ourquantitative findingsandinformtheimplementation ofpeermentoring
programs.
V. Privacyand Confidentiality (Privacyreferstopersonsandtotheirinterestincontrolling theaccess
ofothers to themselves.) (Confidentialityrefers toprotecting information fromunauthorized disclosure
orintelligible interception.) (Investigator shouldcontactthePrivacyOfficerforadditional details.)
1.Indicatethe typeof datathatwillbe received by the Principal Investigator. Check allthat
apply.
Page26 of 33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
1.1.De-identified -Withoutanyidentifiers thatcouldlinkthe data toa specificparticipant.
(ContactPrivacyOfficerforassistance. Ifdataiscoded,itisnotconsidered de-
identified.)
1.2.XIdentified -Linkedto a specific participant byidentifiers sufficient toidentify
participants. (SeeHIPAAandCommon RuleCriteriaforlistofidentifiers.)
1.3. Coded- Linkedtoa specificsubject bya code ratherthan a direct identifier. Ifcoded
ischecked, specify:
1.3.1 Explain who willmaintain thelinkorcode.
1.3.2 Describe whowillhaveaccesstothelinkorcode.
1.3.3 Provide exactdetailsforhowthedataiscoded.
1.3.4
Doesthe project requirethe useofexistingProtected HealthInformation (PHI)froma
database, medical records, orresearch records? X YESQNOQN/A
2.1.Ifyes,
2.1.1. Specifythe source ofthe existingPHIVISN4VAElectronic Records
2.1.2.Indicate the specific dataelements/identifiers (e.g., name, address, phone
numbers, etc.)onthebelowtable.Seebelow:
Forcontact purposes andtracking:name, address, phone numbers, date of birth,and social
security number.
Fordetermining eligibility: diagnosis codesofdiabetes, HbAlc levels, and dateofbirth.
Pleaseseetheattached HIPPAwaiverrequesting permission toaccessthisdata.
2.2. If thestudyusesan existing database/data warehouse,
2.2.1.Provide a description ofthe database/data warehouse. Toidentify
potential eligibleparticipants we willpullnamesfromthe VISN4data
warehouse.
2.2.2. Makeclearwho isresponsible for maintaining it. This warehouse is
maintained bytheVISN.
2.2.3. Citeany relevant Standard Operating Procedures (SOP) forthe database/data
warehouse. N/A
2.2.4. ProvideacopyoftheSOP.
WillPHIbecollectedpriortoobtaininginformedconsent? XYESQNODN/A
3.1.1. Ifyes, completeand provideaHIPAAWaiverof Individual Authorization for
Disclosure ofProtected HealthInformation withthissubmission.
HIPAAIdentifiers -IndicatethePHIthatwillbecollected fromprojectparticipants directly or
indirectly.
4.1.XName
4.2. X Allgeographic subdivisionssmallerthan a State, including street address, city,
county,precinct,zipcode, and theirequivalent geocodes, except forthe initialthree
digitsofazipcode if,according tothecurrentpubliclyavailabledatafromtheBureauof
theCensus
4.3. X Allelements ofdates(except year) for datesdirectlyrelated to an individual, and all
agesover89and allelements ofdates (including year)indicative ofsuch age, except
thatsuch agesand elements maybe aggregated intoa singlecategoryofage 90or
older.
4.3.1. X BirthDate  Date of Death
4.3.2.  Dischargedate  Admission date
4.3.3.  Appointment Dates |ElOtherDates (e.g.labtests, x-rays,MRI,etc.)
HbAlcandLDLblooddrawdates,andBPdates
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBFormsPage27 of 33
R&DService (151)
4.4.XTelephone numbers
4.5.Faxnumbers
4.6.Electronic mail addresses
4.7.XSocialSecurity Number
4.8.Medical record numbers
4.9.Health plan beneficiary numbers
4.10.Account Numbers
4.11.Certificate/license numbers
4.12.  Vehicle identifiers and serial numbers, including licenseplatenumbers
4.13. Device identifiers andserialnumbers
4.14.  Webuniversal resource locators(URLS)
4.15.  Internet protocol(IP) addressnumbers
4.16.Biometric identifiers, includingfingerprints, voiceprints, audio recordings
4.17. Full-facephotographic images and any comparable images
4.18. Anyother unique identifying number, characteristic, orcode
4.19.XPersonal andFamilyHistory
4.20.  HistoryandPhysicalExamination  Progress Notes
4.21.  Discharge Summary(ies) Photographs, videotapes, other images
4.22.X-Ray HIV(testingorinfectious disease)records
4.23.XDiagnostic/Laboratory tests  Sicklecellanemia
4.24.  DrugAbuseInformation Behavioral Healthnotes
4.25.  Alcoholism orAlcoholUse  OperativeReports
4.26.  Billingrecords XMedication List
4.27.  HealthSummary Reports Anatomic Pathology Report
4.28.lElOther Records: Sexandrace
5.Willparticipants becontacted fromexistingPHI?XYESDNODN/A
5.1.Ifyes, clearlyexplainhowparticipants willbecontacted (NOTE:thiswouldbe thesame
information aslistedundersectionR.8identification andrecruitment ofsubjects).
Potential participantonce identified willfirstbesenta letterof introduction lettingthem know
about the studyand givingthem a numberifthey wouldlikemoreinformation orwouldlikeforus
notto callthem. Aweek after mailingout the letter potential participants willbe called and the
studywillagain be introducedtothem and they willbe asked ifthey wouldbe interested in
participating inthe study. Seeattached letterofcontactand scriptfordiscussingthe projectwith
potential participants on thephone.
6.Providethetitlesoftheexactindividuals whowillhaveaccesstothecollected data.
6.1.Explainwhy theseindividual willhaveaccessto this data.
Thetitles oftheindividuals with accessarePrinciple Investigator, ProjectManager, Program
Specialist and DataBase Programmer. Theywillhaveaccesstoidentify,select,and enroll
participants to be part of thestudy.
W. Information Security (ContacttheInformation SecurityOfficerforadditional assistance regarding
confidentiality (storage/security) ofresearch data.)
1.Providethe precise planhowdata istobe collectedoracquired(repeatthesame information
aslistedunder"DataCollection" section ofthisform.
Surveyswillbereadtoparticipants andanswerswilleitherbedirectlyinputintoacomputerdatabase
orwrittenontopaperformsandthentransferred toadatabase ata later time.Thedatabase will
resideon VAserversbehindtheVAfirewall andwillneverberemoved fromtheserver.Paper
Page28 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
recordswillbe stored at CHERPbehindanelectronically lockedentrance, a key-locked doorand ina
key-locked cabinet.
Qualitative interviews willalso be read to participantsand answers willvoicerecorded. Interview
datawillbestoredon theVAserverbehindVAfirewalls. Data about the numberofcalls per month
madebythementorwillbecollectedoverthephone,andagainresponses willeitherbeentered
directlyintoadatabase orfirstonto paper and then intothedatabase.
Dataabouthypoglycemic symptoms willbecollectedoverthephone,andresponses willeitherbe
entereddirectlyintoadatabase orfirstontopaperandthen ontothe database.
Labresultswillbeobtained fromthelab or via CPRSandenteredintothesecureresearch database.
2.Providealistingoftheexact researchdatathat willbestored,includingbutnotlimitedtosigned,
originalinformedconsentand HIPAAauthorization forms,casereportforms,etc.
Hbalc,bloodpressure, directLDL,BMI,self-reported demographics, surveydataexamining diabetes
qualityoflife,depression symptoms, hypoglycemic symptoms, attachment style,goalcommitment,
diabetes health history,general health history,self-efficacy, self-management behaviors,
hypoglycemic symptoms, informedconsentform,HIPPAauthorization form,andexitinterview
data.Indicate howproject'sresearch data (originalandallcopies)willbe storedand provide
corresponding securitysystems.
Data must be used, stored, and securedaccording tothe requirements ofthe VHAseries1200
Handbooks, otherapplicable VAandVHArequirements, andasdescribed intheapproved research
protocolorasspecifically described inthePreparatory toResearch Form.
CHERPNAS isa NetworkedAttached Storageserverinsidethe VAnetwork.Itprovides spaceto
storeelectronic dataforallCHERP/CEPACT-related studies. Itruns IntelXeon 5600 series3GHz
(64bit)CPUswith48GBRAMand146GBharddrive.Accessislimitedtothestudystaffbythe
database administrator.
Hardcopy-based researchdatawillbestoredattheCMCVAMedicalCenterAnnex,(fileroom17)in
afilingcabinetonthesecond floor.ThisroomislocatedatCHERP,whichissecured byalockand
key,andthefilingcabinetcontaining thedatawillbesecuredbylockandkey.Whilefilesareactively
inuse,paperrecordswillbeheldintheCMCVAMedicalCenterAnnexPROMISE (suite200)ina
key-locked filingcabinetbehindanelectronically lockedentranceandakey-locked door.Thedata
willbetransported betweentheCMCVAMC hospitalandCMCVAMC Annexinalockedcase.
3.Indicatehowproject'sresearchdata (originalandallcopies)willbestoredand provide
corresponding securitysystems. Projectresearchdatabothoriginalandcopies forhard-
copieswillbe keptonVA propertyunderlockandkeyin filingcabinets. Electronic data
will bekeptsecureinpassword protected databases.
4.CMCVAMC, provideexactlocationwhereresearchdata(originalandallcopies)willbestored
andsecured.
TheCHERP/CEPACT servers are located inthe secureCMCVAMC serverroom,whichistheOI&T
ServerRoomthat has doublelocksand a securityalarmandcameras, whichislocated inRoom001
ofBuilding1 ofthemainCMCVAMC.
Page29 of33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
Thefilingroomonthesecond flooroftheAnnexand islocatedatRoom17,andthecabinetis locked
inside of Room 17.Activefiles willbestoredina locked filingcabinet(M133)inPROMISE, Suite 200,
located onthesecond flooroftheAnnex.
5.Explainhowdata isto betransported ortransmitted fromonelocationto another. ADA
transcription will give usspaceontheirsecured servertosaveourdata until it is
transcribed thenwewilleraseeverything ontheirserver.
5.1.InformedConsentdiscloses PHItransported ortransmitted off-site.[x]YESNO
N/A
5.2.HIPAAAuthorization discloses entitiesto whomPHIwillbetransportedor transmitted. 
YESKlNODN/A
5.2.1. Listallentitiesorindividuals outside CMCVAMC towhomdataistobe
disclosed, and the justificationfor suchdisclosure and the authority. ADA
Transcription, so the qualitative interviewscan be transcribed. We do not have
themanpower onstafftotranscribe.
5.3.Ifyes, listthe exactdatathatwillbe transmitted. Sept2015-Dec 2015
5.4.Ifyes, explain how datawillbe protected duringtransmission outside of CMCVAMC. This
datawillbeonsecured serverswithcompanies thattheCMCVAMC previously
workedwithandapproved. Inaddition, ADAhassignedaconfidentiality andnon
disclosure agreement.
5.5. Off-site,provide exactlocationADATranscription 127KingsRoadWestampton, NJ
08060(Ifoff-site, attachatleastoneofthefollowing.)
5.5.1. Data Use/Transfer Agreement KlYESDNOXN/A
5.5.2.Off-SiteStorage/Transfer ofResearch DataDYES QNOXN/A
5.5.3.Memorandum ofUnderstanding DYESDNOXN/A
5.5.4.(Note:VAdatadisclosed toa non-VAinvestigator atanacademic affiliatefor
research purposes needstobe approvedbythe UnderSecretaryof Healthor
designee.)
6. Listwho is to haveaccesstothedataandhowtheyaretoaccessit(anyone whohasaccessto
thedataisresponsible for itssecurity).
JudithLong,MD,AnneCanamucio, Jennifer Gutierrez, TanishaDicksandRichardSorrelle, willhave
fullaccessto the data, throughthe secureelectronic serverand the hard copy paper-based data in
thelockedcabinets. ADATranscription willhaveaccesstothequalitative interviews
7.Describe who is to haveaccessandberesponsible forthesecurityoftheinformation (e.g., the
Coordinating Center, the statistician, and PIwho hasultimateresponsibility).
JudithLongwhoisthe PrincipleInvestigator, AnneCanamucio, JenniferGutierrez whoisthe project
manager, andTanisha DicksandRichardSorrelle,whoare theprogramspecialists, willhavefull
accesstothedataandberesponsible forthesecurityoftheinformation.
8.Provide mechanisms usedtoaccount fortheinformation.
The PIwillhave oversight over all information. Hardcopy-based research datawillbe stored at the
CMCVAMedicalCenterAnnex,(fileroom) ina filingcabinet. This room is located at CHERP, which
issecured bya lockandkey,andthefilingcabinetcontaining thedata willbesecured bylockand
key.Paper recordsthatare activelyinusewillbeheldintheCMCVAMedicalCenterAnnex
PROMISE (suite200)onthe second floor,inakey-locked filingcabinetbehindanelectronically
lockedentrance andakey-locked door.
Page30 of 33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
CHERPNAS isaNetworked Attached Storage server insidetheVAnetwork. Itprovidesspaceto
store electronicdata forall CHERP/CEPACT-related studies. ItrunsIntelXeon5600 series3GHz
(64bit)CPUswith48GBRAMand146GBharddrive.Accessislimitedtothestudystaffbythe
database administrator.
9.Givesecuritymeasures thatmustbeinplacetoprotectindividually identifiable information if
collected orused.
Allidentifiable information collectedbyhardcopypaper-baseddata willbe kepton VApropertyunder
lockandkeyinthecabinetlocatedinthelockedfileroom.Allelectronic datawillhavelimitedaccess,
grantedonlytostudystaff,includingtheprincipleinvestigator andtheprogramspecialistunder
supervision ofthedatabase administrator.
10.Howand towhoma suspected or confirmed lossofVAinformation isto bereported.
CMCVAMC Information SecurityOfficerandPrivacyOfficerwillbenotifiedwithinonehourofthe
improperuseordisclosure, aswellastheIRB,Associate ChiefofStaffforResearch (ACOS/R) and
Research Compliance Officer.
11.Identifyanycircumstances thatmaywarrantspecialsafeguards toprotecttherightsand
welfareofsubjects whoarelikelytobevulnerable including, butnotlimitedto,thosesubjects
whomaybesusceptible tocoercionorundueinfluence, anddescribeappropriate actionsto
providesuchsafeguards.
Notapplicable. Wewillnotberecruitingpatientswhoareconsidered vulnerable populations orthose
susceptible tocoercion orundueinfluence.
12.Electronic PHI willbestoredonthefollowing:
12.1.CMCVAMC desktopcomputer withpassword protection and/orencryption. KlYES
NODN/A
12.1.1. Ifyes,identifywhere the desktop islocated. TheCMCVAMC desktops are
password protected, but not encrypted. Thedesktops willbe located at
CMCVAMCottheCMCVAMCAnnex.Electronic PHIwillbestoredon
VAservers behindtheVAfirewallandwillnotberemoved.
12.2.PVAMCsecureserver.XYESQNOQN/A
12.2.1. Ifyes,identifytheCMCVAMC server.VISN4,CMCVAMC/CHERP.
CHERPNAS is a Networked Attached StorageserverinsidetheVAnetwork. It
providesspace tostore electronic dataforallCHERP/CEPACT-related
studies. ItrunsIntelXeon5600series3GHz(64 bit)CPUswith48GB RAM
and146GBharddrive.
12.2.2.Externaldrivethatispasswordprotectedand/orencrypted. DYESXNOD
N/A
12.2.2.1. Ifyes, identify theexternaldrive.
12.3.Off-SiteserverDYESXNOflN/A(Ifoff-site,attach at least one ofthe following.)
12.3.1. Provideexactlocation andthenameoftheoff-siteserver.
12.3.2. Data Use/Transfer AgreementDYES DNOXN/A
12.3.3.Off-SiteStorage/Transfer ofResearch DataDYESDNOXN/A
12.3.4. Memorandum ofUnderstanding DYESDNOXN/A
13.Explainhowdataistobe transported ortransmitted fromonelocationtoanother.ADA
transcription hassecureservers.
14.InformedConsentdiscloses PHItransported ortransmitted off-site.XYESDNOQN/A
Page31 of 33
HRPPApproval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService (151)
15.HIPAAAuthorization discloses entitiesto whom PHI willbetransported ortransmitted.
XYESDNODN/A
16.Listallentitiesor individuals outsideCMCVAMC to whom dataisto bedisclosed, and the
justification forsuchdisclosure andtheauthority. AlphaTranscription inordertotranscribe the
qualitative interviews andtheMixedMethodsResearch Labinordertocodethe interviews
17.Clarifywhatprotection existsforadatabase. Accessislimitedtothestudystaffbythe
database administrator.
17.1.Dataisstored:
17.1.1. Withidentifiers - XYES DNO
17.1.2. Coded-^YES DNO
17.1.3. De-Identified - DYES lElNO
17.1.4. Providetheexactlist ofidentifiers thatwillbestored.Name,socialsecurity
number,phonenumber,address, dateofbirthand age.
18.Describetheplanforprotecting researchdata fromimproperuseordisclosure. OnlyIRB
approvedstudypersonnel willhaveaccess to studyrelatedmaterials. Studyrelatedmaterials
willbekeptinpassword protected filesona secure server.Paperfileswillbekeptonthe
premises inlockedfilingcabinets.
18.1.TheInvestigator mustnotifytheInformation SecurityOfficer,PrivacyOfficer,IRB,
Associate Chief of Staff for Research andResearch Compliance Officerwithin onehour
oftheimproper useordisclosure.
19.IsthereaplantoapplyforaCertificate ofConfidentiality? DYESQNO|E]N/A
19.1.Ifyes,provideacopyofthecertificate withthisapplication ortotheIRBOfficeas soon
asreceived.
20.Record Retention:
20.1.Therequiredrecords,includingtheinvestigator's researchrecords,mustberetained
untildisposition instructions are approvedbythe NationalArchivesand Records
Administration and are publishedin VHA'sRecordsControlSchedule (RCS 10-1).VHA
Handbook 1200.05 §26.h
20.2.Untilaschedule forlocalresearch records ispublished, ALLrecordsincluding identifiers
mustberetained." ORO/ORD Guidance onInformed Consent FormModifications
Addressing VARecord Retention Requirements (July23, 2009)
20.3.Ifthereare additional procedures forrecord retention,explainfurther. None
X.Qualification oftheInvestigators
Provideadescription ofthequalifications ofeachinvestioator/co-investigator andtheirspecific
roleinthestudy.
JudithA.Long,MDistheprimaryinvestigator onthisstudy.Sheisanexperienced researcher
intheareasofsocialdeterminants ofhealth, health disparities, and Diabetes Mellitus. Sheis
anAssociate Professor ofMedicineinthe DivisionofGeneralInternal Medicineat the Penn
SchoolofMedicine (SOM),theDirectorofthePenn SOMMastersofScienceinHealthPolicy
Research (MSHP),thePrincipalInvestigator (PI)forthePennNRSAGeneralist Research
TrainingGrant,Associate DirectorofthePennRobertWoodJohnsonClinicalScholars
Program(RWJCSP)andCo-ChairoftheSocietyforGeneralInternalMedicine(SGIM)
Page32 of 33
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms
R&DService(151)
Disparities TaskForce.Shehasmorethan10yearsofexperience inclinicaldiabetes
management. Recently,herresearchhasfocusedoninterventions toreducedisparities in
healthdirectingclinicalresearchtrialsfocusingondiabetes.SherecentlycompletedaVA
basedrandomized controlled trial(RCT)ofpeermentoring andfinancialincentives foradults
withpoorlycontrolledtype2diabetesandiscurrentlythePIforasimilarNIDDK-funded clinical
RCTwhichisbeingimplemented inanonVAlow-income minoritypopulation. ThisR01also
includescosteffectiveness analysessimilartothoseproposedhere.Shealsohasamulti-site
HSR&D MRevaluating deliveryofcareforpatientswithbothdiabetesandseriousmental
illness.Shewillbe responsibleforthe oversight ofthisentire study.
1.Ifapplicable, thePrincipalInvestigator mustidentifyaqualifiedcliniciantoberesponsible forall
study related healthcare decisions.
Therewillbenostudyrelatedhealthcare decisions. Dr.Longwillreviewallseriousadverseeventsand
determine ifthey are potentiallystudy related.
2. PIshouldsubmita current, datedCVwitheachnewinitialreview.
Pleaseseeattached CV forJudithLong, MD.
Page33 of 33
HRPP Approval: 06/15/2011
R&DApproval: 07/05/2011
File:K:NewIRBForms